Effect of nateglinide on the incidence of diabetes and cardiovascular events.
BACKGROUND: The ability of short-acting insulin secretagogues to reduce the risk of diabetes or cardiovascular events in people with impaired glucose tolerance is unknown. METHODS: In a double-blind, randomized clinical trial, we assigned 9306 participants with impaired glucose tolerance and either...
Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Médium: | Journal article |
Jazyk: | English |
Vydáno: |
2010
|